CN102228581B - Chinese herbal medicine for treating rhinitis - Google Patents
Chinese herbal medicine for treating rhinitis Download PDFInfo
- Publication number
- CN102228581B CN102228581B CN2011101672233A CN201110167223A CN102228581B CN 102228581 B CN102228581 B CN 102228581B CN 2011101672233 A CN2011101672233 A CN 2011101672233A CN 201110167223 A CN201110167223 A CN 201110167223A CN 102228581 B CN102228581 B CN 102228581B
- Authority
- CN
- China
- Prior art keywords
- rhinitis
- medicine
- treating
- chinese herbal
- herbal medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a Chinese herbal medicine for treating rhinitis, which comprises Astragalus, white atractylodes rhizome, divaricate saposhnikovia root, white paeony root, cassia twig, as arum, Schisandra chinensis, ephedra, paniculate swallowwort root and rhizoma acori graminei. The Chinese herbal medicine has the effects of tonifying and reducing, dispelling and absorbing the stasis, moistening the lung and consolidating superficial resistance, dispelling cold and removing phlegm, and dredging collaterals and stopping nose mucus, is used for treating various rhinitises, particularly perennial allergic rhinitis, solves the problems that the conventional medicine for treating the rhinitis is long in therapeutic period and the rhinitis is easy to relapse and cannot be cured once for all, and has the advantages of low cost, good therapeutic effect, quickness in radical cure and the like.
Description
Technical field
The present invention relates to a kind of Chinese medicine, relate in particular to a kind of Chinese medicine of treating rhinitis.
Background technology
Rhinitis (Rhinitis) refers to the inflammation of nasal membrane and submucous tissue.The clinical symptoms of rhinitis morbidity is different, very harmful, when influencing the physiological function of nasal cavity; Respiratory disorder can appear; Cause blood oxygen concentration and reduce, influence the function and the metabolism of other tissue and organ, and some occur like headache, dizzy, hypomnesis; Chest pain, uncomfortable in chest, lethargy etc., in addition can concurrent emphysema, severe complications such as pulmonary heart disease, asthma.And fail to get timely medical treatment when rhinitis, when influencing the olfactory sensation mucosa, olfactory disorder will appear, cause hearing not good and foul smells grade for abnormal smells from the patient.When the sinusitis of prolonged and repeated outbreak is not got timely medical treatment; Inflammation will diffuse to adjacent organs, tissue, and concurrent like multiple critical emergency cases such as osteomyelitis of frontal bone, socket of the eye bone wall osteitis and periostitis, subperiosteal orbital abscess, orbital cellulitis, retrobulbar neuritis, spinal epidural absceess, subdural abscess, purulent meningitis, brain abscess, cavernous sinus thrombophlebitiss.
Aspect work and study, the adult can be because rhinitis causes headache, and brain is not clear-headed, has dizzy spells, and makes work efficiency low; Then because symptoms such as the nasal obstruction that rhinitis causes, headache cause distraction, memory and school grade significantly descend teenager.Other complication that rhinitis caused also have: because of the stuffiness of long-time nasal obstruction, dyspnea can cause sleep apnea syndrome; Patient's hypertrophic inferior turbinate, oxygen is not enough during sleep, can cause cerebral infarction, hypertension, heart attack etc. under the serious situation, individual patient even meeting sudden death at night.
Along with urban life modernization day by day, vehicle exhaust, cosmetics, ornament materials and food additive etc., these all are the main causes that causes rhinitis (comprising allergic rhinitis, chronic rhinitis, chronic sinusitis or the like).The number of suffering from rhinitis at present is more and more, and the age trend becomes younger.Rhinitis patient increases year by year, and the harm of human body more can not be ignored, and getting rhinitis must in time treat, and does not necessarily let the rhinitis development lead to serious disease.
Doctor trained in Western medicine thinks that rhinitis owing to heating common cold toxinfection causes, often adopts therapeutic schemes such as antibiotic bactericidal antiphlogistic, operation, laser in the treatment, though the ability instant effect, painful big, easy recurrence and medical expense height.The traditional Chinese medical science thinks, primary disease is because visceral dysfunction and individual natural endowment body constitution are relevant, and exopathogenic factor is many is attacked due to the nose key by weather (wind, cold, hot, dry etc.) pathogen.Visceral dysfunction and lung, spleen, kidney three internal organs are deficient relevant, and its disease is mainly at lung, and it is at the spleen kidney.Common disease type has: Qi deficiency blood stasis type, kidney yang deficiency, pattern of fever in the exogenous cold.Therapeutic scheme often adopts the method for clothes decoction, and uncertain therapeutic efficacy is cut, and oral inconvenience is not portable, though occur the Chinese patent medicine of many treatment rhinitis on the market, therapeutic effect is unsatisfactory, easy relapse, and treatment cycle is long, and expense is also than higher.
Summary of the invention
The objective of the invention is deficiency, provide a kind of easy to use, the Chinese medicine of eutherapeutic treatment rhinitis to prior art.The Chinese medicine that the present invention treats rhinitis can be made into drop (spray) or tablet, capsule, granule.
The technical scheme that the present invention adopted is:
A kind of Chinese medicine of treating rhinitis; By weight percentage, said medicine is by being made up of windproof, the Radix Paeoniae Alba of 5-15% of the Rhizoma Atractylodis Macrocephalae of the Radix Astragali of 15-30%, 5-15%, 5-15%, the Ramulus Cinnamomi of 5-15%, the Fructus Schisandrae Chinensis of 5-15%, the Herba Asari of 1-10%, the Herba Ephedrae of 1-10%, the Radix Cynanchi Paniculati of 5-15%, the Rhizoma Acori Graminei of 5-15%.
The preferred proportioning of above-mentioned Chinese medicine is: by weight percentage, said medicine is made up of 25% the Radix Astragali, 8% the Rhizoma Atractylodis Macrocephalae, 8% windproof, 8% the Radix Paeoniae Alba, 8% Ramulus Cinnamomi, 8% Fructus Schisandrae Chinensis, 5% Herba Asari, 5% Herba Ephedrae, 12.5% Radix Cynanchi Paniculati, 12.5% Rhizoma Acori Graminei.
The side separates:
Chinese medicine according to the invention is processed by the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, windproof, the Radix Paeoniae Alba, Ramulus Cinnamomi, Herba Asari, Fructus Schisandrae Chinensis, Herba Ephedrae, Radix Cynanchi Paniculati, Rhizoma Acori Graminei kinds of traditional Chinese medicines, wherein:
The Radix Astragali is a monarch drug, has tonifying Qi and lifting yang, and benefit is defended the effect of consolidating superficial resistance;
Rhizoma Atractylodis Macrocephalae invigorating the spleen and benefiting QI, dehumidifying with in, windproof expelling wind and cold, the Ramulus Cinnamomi warming middle-JIAO that activates yang, three medicines are ministerial drug, help Radix Astragali benefiting QI for strengthening the superficies altogether;
Herba Asari warming YANG to expel cold, dissipating fluid-retention are sensible;
Radix Paeoniae Alba acid is held back and is cloudy;
The Herba Ephedrae expelling cold and relieving exterior syndrome;
Fructus Schisandrae Chinensis convergence lung qi;
The Rhizoma Acori Graminei resuscitation inducing and mind tranquilizing, removing dampness to restore normal function of the stomach;
Radix Cynanchi Paniculati dispels the wind, invigorates blood circulation, detoxifies.
All medicines have both helped the Radix Astragali to consolidate altogether for assistant makes, and unlikely again suffering is loose too.With the medicine of preventing and treating rhinitis that above-mentioned kinds of traditional Chinese medicines raw material is prepared from through certain method, invigorating middle warmer has rushes down, and in loosing receipts is arranged, and plays the warming the lung consolidating superficial resistance altogether, expelling cold and resolving fluid-retnetion, sensible effect of ending tears.
The modern pharmacology experimentation shows; The Radix Astragali, the Rhizoma Atractylodis Macrocephalae, windproof effect with two-ways regulation immunologic function; Can improve the intravital hypersensitive state of allergic disease patient; Can suppress generation and the mastocyte release of active agent of IgE through replenishing various trace elements adjustment body's immunological function such as several amino acids and selenium, zinc, copper, reach antianaphylactic effect through enhancing human body immunity power.The Radix Paeoniae Alba, Fructus Schisandrae Chinensis, Radix Cynanchi Paniculati, Rhizoma Acori Graminei have antiinflammatory and immunoregulation effect.And Ramulus Cinnamomi, Herba Asari all can reduce the release of sensitive media to some extent.The ephedrine that Herba Ephedrae includes has the vasoconstriction effect, and to eliminating nasal mucosa swelling, improving ventilation has good therapeutic effect.
The function of medicine of the present invention cures mainly: be used to treat various rhinitis, be particularly useful for treating the perennial allergic rhinitis.
Dose:
The external drop, the collunarium chamber was 3-4 time on 1st, and each 2-3 drips;
Oral: as 2 times on the one, to obey 1-10g at every turn.Be 7 days 1 course of treatment, serve on for 4 courses of treatment.
The method for preparing of medicine according to the invention may further comprise the steps:
A, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, windproof, the Radix Paeoniae Alba, Ramulus Cinnamomi, Herba Asari, Fructus Schisandrae Chinensis, Herba Ephedrae, Radix Cynanchi Paniculati, Rhizoma Acori Graminei are mixed, and with this mixture and the mixed of water according to weight ratio 1:8-1:10, immersion is 30-60 minute in water according to weight proportion;
B, mixture in the steps A and decocting were boiled 30-60 minute, filter and obtain first filtrating and the filtering residue;
C, with among the step B the filtering residue of winning and water according to the mixed of weight ratio 1:5-1:10, again it was decocted 30-60 minute, filter then and obtain second filtrating and the filtering residue, first filtrating and second is filtrated is mixed.
Above-mentioned medicinal liquid can be processed nasal drop, spray, wafer, granule or tablet as required respectively, and method for preparing is the conventional process in this area.
Pharmacology pharmacodynamic research
1. acute toxicity test
The mouse stomach said preparation is under possible dosage, and single administration median lethal dose(LD 50) LD50 can not measure, so maximum tolerance determination is carried out in this test.The result: maximum tolerated dose is greater than 6g/kg, and by normal adult body weight 50kg, medication every day 1g calculates, behave 300 times of clinical consumption of tolerance multiple.
2. long term toxicity test
This medicine is for the normal rat nasal-cavity administration, and dosage is equivalent to 60 times of people's clinical administration dosage, continuous 3 months, the 6-10 that is equivalent to people's administration time doubly, local toxicity, zest do not appear in the result, do not have general toxicity yet and change.Portion of this officina administration safety, nontoxic is described.
3. local irritation
The stimulation of rat nasal membrane: normal rat bilateral nasal cavity is splashed into said preparation, each 0.3ml/kg, once a day, successive administration 14 days was put to death animal on the 15th day, got nasal membrane and carried out pathological examination, HE dyeing, the no abnormal finding of result.Show that said preparation does not have the obvious stimulation effect to medicine-feeding part.
Stimulation to lagophthalmos: splash into said preparation 0.1ml in the rabbit cornea capsule of being in, administration is after 1 hour, rabbit cornea color and luster no change, and no hyperemia etc. stimulate phenomenon.
4. hypersensitive test
Get healthy guinea pig and inject said preparation 0.5ml every day, inject altogether 3 times.And inject original liquid 1ml from jugular vein in injection after 14 days for the first time and after 21 days respectively.Injecting anaphylaxiss such as not having excited uneasiness, dyspnea, death by suffocation within a few minutes, the prompting said preparation does not have irritated the reaction.
Drug action
1. antiinflammatory action: (0.8ml/kg 0.4ml/kg) directly is applied to the surface of the mice swelling ear due to the Oleum Tiglii to large and small two dosage of said preparation, and the suppression ratio of its swelling is respectively 32.1%, 27.7%.The effect of the mice ear due to the anti-Oleum Tiglii of said preparation is superior to contrasting medicine; Do not ooze out the method test through rat Intradermal pigment, smear said preparation 0.15ml/kg in the depilation rat abdomen, 0.3ml/kg, its dyeing area is checked through t, the P value is respectively P>0.05, < 0.05,>0.05.
2. to the effect of mice nosal inflammation model: drip after the mice nasal cavity causes the nosal inflammation model with xylene, nasal cavity gives said preparation 0.4ml/kg, 0.8ml/kg.After putting to death animal, get nose and carry out pathological examination, the result shows, administration after modeling can promote inflammation to recover, and reduces the downright bad generation of inflammation, and effect is better than the contrast medicine.
Clinical trial
Selecting acute and chronic rhinitis (the anemopyretic cold nasal obstruction of the traditional Chinese medical science) is the object of observation, observes 600 examples altogether.The result shows that said preparation can improve nasal obstruction, concha nasalis swelling, and degradation symptom under the BITONG tolerance, treatment group total effective rate is 95.0%, cure-remarkable-effectiveness rate is 88.0%; The matched group total effective rate is 67.8%, and cure-remarkable-effectiveness rate is 45.6%; Two groups of significant differences, P < 0.01.
In addition, patient's routine blood test, routine urinalysis, liver function, kidney merit, electrocardiogram detect all and take place unusually before and after this preparation for treating, and normal person's nasal mucosa ciliary movement is also had no effect, and point out this preparation clinical drug safety reliable.
The specific embodiment
Embodiment 1
Get Chinese crude drug Radix Astragali 15g, Rhizoma Atractylodis Macrocephalae 15g, windproof 15g, Radix Paeoniae Alba 15g, Ramulus Cinnamomi 15g, Fructus Schisandrae Chinensis 5g, Herba Asari 5g, Herba Ephedrae 5g, Radix Cynanchi Paniculati 5g, Rhizoma Acori Graminei 5g, add water 800g and mix, soaked 30 minutes, decocted 30 minutes, filter and obtain first filtrating and the filtering residue; Weight ratio according to 1:5 in above-mentioned filtering residue adds entry, decocts 30 minutes, filters then to obtain second filtrating and the filtering residue.First filtrating is mixed with second filtrating, process nasal drop spray alive according to common process.
Embodiment 2
Get Chinese crude drug Radix Astragali 30g, Rhizoma Atractylodis Macrocephalae 5g, windproof 5g, Radix Paeoniae Alba 5g, Ramulus Cinnamomi 5g, Fructus Schisandrae Chinensis 5g, Herba Asari 10g, Herba Ephedrae 10g, Radix Cynanchi Paniculati 15g, Rhizoma Acori Graminei 15g, add water 1000g and mix, soaked 30 minutes, decocted 60 minutes, filter and obtain first filtrating and the filtering residue; Weight ratio according to 1:10 in above-mentioned filtering residue adds entry, decocts 60 minutes, filters then to obtain second filtrating and the filtering residue.First filtrating is mixed with second filtrating, process wafer according to common process.
Embodiment 3
Get Chinese crude drug Radix Astragali 23g, Rhizoma Atractylodis Macrocephalae 10g, windproof 10g, Radix Paeoniae Alba 10g, Ramulus Cinnamomi 10g, Fructus Schisandrae Chinensis 15g, Herba Asari 1g, Herba Ephedrae 1g, Radix Cynanchi Paniculati 10g, Rhizoma Acori Graminei 10g; Adding water 1000g mixes; Soaked 50 minutes, decocted 40 minutes, filter and obtain first filtrating and the filtering residue; Weight ratio according to 1:8 in above-mentioned filtering residue adds entry, decocts 50 minutes, filters then to obtain second filtrating and the filtering residue.First filtrating is mixed with second filtrating, process granule according to common process.
Embodiment 4
Get Chinese crude drug Radix Astragali 25g, Rhizoma Atractylodis Macrocephalae 8g, windproof 8g, Radix Paeoniae Alba 8g, Ramulus Cinnamomi 8g, Fructus Schisandrae Chinensis 8g, Herba Asari 5g, Herba Ephedrae 5g, Radix Cynanchi Paniculati 12.5g, Rhizoma Acori Graminei 12.5g, add water 900g and mix, soaked 40 minutes, decocted 50 minutes, filter and obtain first filtrating and the filtering residue; Weight ratio according to 1:9 in above-mentioned filtering residue adds entry, decocts 50 minutes, filters then to obtain second filtrating and the filtering residue.First filtrating is mixed with second filtrating, process tablet according to common process.
Claims (2)
1. Chinese medicine of treating rhinitis; It is characterized in that; By weight percentage, said medicine is made up of windproof, the Radix Paeoniae Alba of 5-15% of the Rhizoma Atractylodis Macrocephalae of the Radix Astragali of 15-30%, 5-15%, 5-15%, the Ramulus Cinnamomi of 5-15%, the Fructus Schisandrae Chinensis of 5-15%, the Herba Asari of 1-10%, the Herba Ephedrae of 1-10%, the Radix Cynanchi Paniculati of 5-15%, the Rhizoma Acori Graminei of 5-15%.
2. the Chinese medicine of treatment rhinitis according to claim 1; It is characterized in that; By weight percentage, said medicine is made up of 25% the Radix Astragali, 8% the Rhizoma Atractylodis Macrocephalae, 8% windproof, 8% the Radix Paeoniae Alba, 8% Ramulus Cinnamomi, 8% Fructus Schisandrae Chinensis, 5% Herba Asari, 5% Herba Ephedrae, 12.5% Radix Cynanchi Paniculati, 12.5% Rhizoma Acori Graminei.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101672233A CN102228581B (en) | 2011-06-21 | 2011-06-21 | Chinese herbal medicine for treating rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101672233A CN102228581B (en) | 2011-06-21 | 2011-06-21 | Chinese herbal medicine for treating rhinitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102228581A CN102228581A (en) | 2011-11-02 |
| CN102228581B true CN102228581B (en) | 2012-11-21 |
Family
ID=44841213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101672233A Expired - Fee Related CN102228581B (en) | 2011-06-21 | 2011-06-21 | Chinese herbal medicine for treating rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102228581B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784342A (en) * | 2012-09-01 | 2012-11-21 | 范文忠 | Medicament for treating chronic bronchitis and preparation method thereof |
| CN103110750B (en) * | 2012-12-11 | 2016-03-16 | 陈文忠 | Traditional Chinese medicine for treating rhinitis |
| CN105267625A (en) * | 2014-07-02 | 2016-01-27 | 李一圣 | Traditional Chinese medicine compound for treating allergic rhinitis based on Lingnan Chinese herbal medicines and preparation method of traditional Chinese medicine compound |
| CN105311268A (en) * | 2014-07-02 | 2016-02-10 | 李一圣 | Compound traditional Chinese medicine for treating allergic rhinitis and preparation method thereof |
| CN104288371A (en) * | 2014-10-22 | 2015-01-21 | 孙爱华 | Traditional Chinese medicine composition for treating perennial allergic rhinitis, preparation method and application |
| CN106389768A (en) * | 2016-11-07 | 2017-02-15 | 吉林大学 | Medicine composition for treating nasal diseases and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101264190A (en) * | 2008-04-21 | 2008-09-17 | 北京中科仁和科技有限公司 | Chinese medicinal composition treating allergic rhinitis and preparation thereof |
| CN101537089A (en) * | 2008-03-21 | 2009-09-23 | 北京中泰天和科技有限公司 | Pharmaceutical composition for curing allergic rhinitis and preparation method thereof |
-
2011
- 2011-06-21 CN CN2011101672233A patent/CN102228581B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101537089A (en) * | 2008-03-21 | 2009-09-23 | 北京中泰天和科技有限公司 | Pharmaceutical composition for curing allergic rhinitis and preparation method thereof |
| CN101264190A (en) * | 2008-04-21 | 2008-09-17 | 北京中科仁和科技有限公司 | Chinese medicinal composition treating allergic rhinitis and preparation thereof |
Non-Patent Citations (2)
| Title |
|---|
| 李国云,俞秋荣.中医药治疗变应性鼻炎的研究进展.《湖北中医杂志》.2010,第32卷(第8期),75－77. * |
| 臧江红.过敏性鼻炎中医药治疗近况.《四川中医》.2010,第28卷(第12期),36-38. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102228581A (en) | 2011-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102228580B (en) | Chinese herbal composition for treating sudden deafness | |
| CN102228581B (en) | Chinese herbal medicine for treating rhinitis | |
| CN1245187C (en) | Medicine for treating eye disease caused by visceral disease | |
| CN100360146C (en) | A Chinese medicine for treating rhinitis and preparation method thereof | |
| CN101342333B (en) | Traditional Chinese medicine for treating cough and asthma and preparation method thereof | |
| CN102813839B (en) | Compound medicine for treating cluster headache syndrome | |
| CN103316146B (en) | Traditional Chinese medicinal preparation for anesthesia | |
| CN103127472B (en) | Traditional Chinese medicine compound for refractory insomnia | |
| CN104208483A (en) | Traditional Chinese medicine composition for treating anaphylactic rhinitis | |
| CN104013868A (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and preparation method thereof | |
| CN102228626B (en) | Traditional Chinese medicine for treating tinnitus and deafness | |
| CN104771602A (en) | Medicine for treating facioplegia and preparation method thereof | |
| CN101647874B (en) | Traditional Chinese medicine liniment for treating epichrosis leucasmus and armpit odor and preparation method thereof | |
| CN103479969A (en) | Medicine for treating manic-depressive psychosis and preparation method thereof | |
| CN106110216A (en) | Treat neurasthenic Chinese medicinal formulae | |
| CN106075311A (en) | One is used for treating neurasthenic Chinese medicine composition | |
| CN103816456B (en) | The pharmaceutical composition for the treatment of cerebral trauma sequela | |
| CN105561002A (en) | Folium artemisiae argyi health-care foot bath powder and preparation method thereof | |
| CN101912498B (en) | Medicament for treating gout and preparation method thereof | |
| CN105194427A (en) | Traditional Chinese medicine composition for treating xerophthalmia and preparation method of traditional Chinese composition | |
| CN104771516A (en) | Traditional Chinese medicine composition for treating allergic dermatitis | |
| CN103405671A (en) | Traditional Chinese medicine for treating glaucoma caused by hyperactivity of liver-yang | |
| CN106110032A (en) | A kind of Chinese medicine treating chronic recurrent oral ulcer | |
| CN105412322A (en) | Traditional Chinese medicine preparation for treating diabetic peripheral neuropathic pain and preparation method thereof | |
| CN104958705A (en) | Traditional Chinese medicine for treating oral ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121121 Termination date: 20130621 |